{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T10:10:46Z","timestamp":1753870246246,"version":"3.41.2"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":1120,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Adalimumab is an anti-tumour necrosis factor administered for the management of severe psoriasis. Previously limited to Humira, new biosimilar medications have now emerged including Amgevita. To date, there have been no comparison studies of adalimumab biosimilar use on different types of psoriasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the implications of biosimilar medications and patient specific factors on clinical outcomes, including Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A clinical notes review was performed for all dermatology patients with adalimumab-controlled psoriasis at our centre. Demographic profile, psoriasis subtype and changes in clinical patterns as demonstrated by PASI and DLQI were extracted and analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 91 records identified, 70 patients met the inclusion criteria. 21 patients (30%) demonstrated significant increase in PASI and DLQI scores with Amgevita. Scores improved to baseline once Humira was restarted. Findings reveal no difference in pre-adalimumab disease severity or mean age between the groups. Patients responding only to Humira had a greater proportion of females, and were likelier to have psoriatic arthritis (odds ratio [OR]: 10.63; p &amp;lt; 0.0002) and nail involvement (OR: 6.13, p &amp;lt; 0.02), compared with patients well controlled with Amgevita.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This audit of a single dermatology centre suggests switching to a biosimilar adalimumab may exacerbate symptoms of psoriasis. Future studies should investigate whether findings are restricted to our study population, and consider the influence of other factors, such as disease subtypes and medication formulations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/ski2.60","type":"journal-article","created":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T07:40:21Z","timestamp":1631950821000},"source":"Crossref","is-referenced-by-count":3,"title":["The Effect of Biosimilar Administration on Clinical Outcomes in Patients with Adalimumab-Controlled Psoriasis"],"prefix":"10.1093","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7977-9317","authenticated-orcid":false,"given":"M.","family":"Panahi","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital , Cottingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Skelly","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital , Cottingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Zaman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital , Cottingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,9,18]]},"reference":[{"volume-title":"Introduction, Psoriasis: assessment and management, Guidance","year":"2017","author":"National Institute for Health and Care Excellence","key":"2025010818021192900_ski260-bib-0001"},{"issue":"2","key":"2025010818021192900_ski260-bib-0002","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"volume-title":"Adalimumab for the treatment of adults with psoriasis. 4-Consideration-of-the-evidence. Guidance and guidelines","year":"2008","author":"National Institute for Health and Care Excellence","key":"2025010818021192900_ski260-bib-0003"},{"issue":"2","key":"2025010818021192900_ski260-bib-0004","first-page":"93","article-title":"Drug focus: adalimumab in the treatment of moderate to severe psoriasis","volume":"1","author":"Vena","year":"2007","journal-title":"Biol Targets & Ther"},{"volume-title":"Assessment Report Amgevita","year":"2017","author":"European Medicines Agency","key":"2025010818021192900_ski260-bib-0005"},{"volume-title":"Biosimilars in the EU \u2013 Information guide for healthcare professionals","year":"2019","author":"European Medicines Agency and the European Commission","key":"2025010818021192900_ski260-bib-0006"},{"issue":"3","key":"2025010818021192900_ski260-bib-0007","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.clinthera.2017.01.031","article-title":"The placebo and nocebo phenomena: their clinical management and impact on treatment outcomes","volume":"39","author":"Chavarria","year":"2017","journal-title":"Clin Therapeut"},{"key":"2025010818021192900_ski260-bib-0008","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaut.2015.07.008","article-title":"The immunogenetics of psoriasis: a comprehensive review","volume":"64","author":"Harden","year":"2015","journal-title":"J Autoimmun"},{"issue":"2","key":"2025010818021192900_ski260-bib-0009","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/14397595.2016.1193105","article-title":"Gender specific differences in patients with psoriatic arthritis","volume":"27","author":"Nas","year":"2017","journal-title":"Modern Rheumatology"},{"issue":"4","key":"2025010818021192900_ski260-bib-0010","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/annrheumdis-2012-201357","article-title":"Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis","volume":"72","author":"Eder","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2025010818021192900_ski260-bib-0011","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2025010818021192900_ski260-bib-0012","doi-asserted-by":"publisher","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British society of rheumatology biologics register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"2025010818021192900_ski260-bib-0013","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1111\/bjd.15857","article-title":"Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"issue":"5","key":"2025010818021192900_ski260-bib-0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.02.1060","article-title":"Single transition from adalimumab to ABP 501: evaluation of immunogenicity in a phase 3 study in subjects with moderate to severe plaque psoriasis","volume":"74","author":"Gooderham","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2025010818021192900_ski260-bib-0015","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000478077","article-title":"The Immunogenicity of Biologic Therapies","volume":"53","author":"Garc\u00eas","year":"2017","journal-title":"Current Problems in Dermatology (Switzerland)"},{"issue":"6","key":"2025010818021192900_ski260-bib-0016","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jaad.2016.12.014","article-title":"Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study","volume":"76","author":"Papp","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"2025010818021192900_ski260-bib-0017","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","article-title":"Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ski2.60","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ski2.60","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/1\/4\/ski2.60\/59726310\/skinhd_1_4_e60.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/1\/4\/ski2.60\/59726310\/skinhd_1_4_e60.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T18:02:23Z","timestamp":1736359343000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/doi\/10.1002\/ski2.60\/7733938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,18]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ski2.60","relation":{},"ISSN":["2690-442X"],"issn-type":[{"type":"electronic","value":"2690-442X"}],"subject":[],"published-other":{"date-parts":[[2021,12]]},"published":{"date-parts":[[2021,9,18]]},"article-number":"ski2.60"}}